Physicians' Academy for Cardiovascular Education

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

10' education - Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

This lecture was part of a CME accredited symposium; SGLT2 inhibition, diabetes and CVD: Where does this fit in CV risk management? held at ESC 2016 in Rome

Video navigation menu

  • Development of anti-diabetic medication over the past years 00:14
  • Anti-diabetic medications target different mechanisms 01:40
  • Working mechanism of SGLT-2 inhibitors 04:10
  • Effectivity of SGLT-2 inhibitors 06:41
  • CV effect of SGLT-2 inhibitors 10:30
  • Effect of SGLT-2 inhibitors on renal function 15:11
  • ADA/EASD position statement for treatment of diabetic patients 17:24

Educational information

Educational objectives of this symposium were to:

CME accreditation

This symposium was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).


Prof Silvio Inzucchi MD, is Professor of Medicine at the Yale School of Medicine in New Haven, Connecticut, US, where he serves as Clinical Chief of the Section of Endocrinology and Medical Director of the Yale Diabetes Center


Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

Also view lecture: Challenging cardiovascular risk in diabetes: ready for a new approach? by prof John Deanfield, MD, University College London, United Kingdom Also view lecture: Heart Failure & Diabetes: SGLT2 inhibition a paradigm shift? by prof John McMurray, MD University of Glasgow United Kingdom

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: